Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
+44 1223 790975
ISSN: 2155-9899
+44 1223 790975
Helieh S Oz
UK Medical Center, USA
Scientific Tracks Abstracts: J Clin Cell Immunol
Millions of people worldwide suffer from chronic inflammatory diseases including periodontitis, hepatitis, pancreatitis, gastrointestinal and neurodegenerative complications which can further lead to malignancies. Inflammation and immune response are required for the tissue defense, regeneration and healing process. Yet, exaggerated and chronic inflammation can advance to life-long debilitation, loss of tissue function and organ failure. Despite the millennial advancements in diagnostic technology and therapeutic modalities, there remains no effective cure for patients who suffer from inflammatory diseases. Therefore, over 40% of patients with inflammatory complications seek some form of complementary and alternative medical (CAM) agents as adjunct therapeutic modalities, to alleviate symptoms and possibly to prevent outcomes of inflammation, whether or not to consent their clinicians. There is not sufficient scientific information or international regulatory enforcements regarding the most available CAM agents which some may interact with patientsâ�?�? current therapies with severe consequences. One of the most investigated agents is Green tea and it polyphenols (GrTP) with potent antioxidants effects. GrTP have important roles in regulating vital signaling pathways comprise transcription nuclear factor-kappa B mediated kappa B kinase complex pathways, programmed cell death pathways like caspases and B-cell lymphoma-2 and intervention with the surge of inflammatory markers like cytokines (e.g. TNF�?±, INF, IL-2, IL-6, IL-10) and production of cyclooxygenase. This workshop will explore mechanism of actions for protective effects of GrTP and some reported adverse effects. In addition, possible applications for GrTP will be presented against chronic inflammatory complications and some food safety applications.
Helieh S Oz has DVM and MS (U. IL); PhD (U. MN) and clinical translational research certificate (U. KY Med Center). Dr. Oz is an active member of American Association of Gastroenterology (AGA) and AGA Fellow (AGAF). Dr. Oz is an immune-microbiologist with expertise in inflammatory and infectious diseases, mucosal Immunity, drug discoveries, pathogenesis, and micronutrient. Dr. Oz was PI recipient for NIH-NCCAM grant to investigate Green tea polyphenols and Inflammatory Diseases. Dr. Oz has over 90 publications in the areas of chronic inflammatory disorders (pancreatitis, hepatitis, colitis, periodontitis), microbial and infectious diseases (e.g. Toxoplasmosis, Trypanosomasis, Babesiosis, Pneumocystis pneumonia). Dr. Oz has served as Lead editor for special issues such as Gut Inflammatory, Infectious diseases and Nutrition (Mediators of Inflammation 2017); Nutrients, Infectious and Inflammatory Diseases (Nutrients 2017); Gastrointestinal Inflammation and Repair: Role of Microbiome, Infection, Nutrition (Gastroenterology Research Practice 2016), and co-editor for Parasitic infections in pediatric clinical practice (J Pediatric Infectious Disease 2016) and Chagas Disease, Intech Open Science 2017. Dr. Oz is a member of editorial board for different advisory committees and an avid reviewer for several peer-reviewed journals.